Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



October 2004, Volume 34 Number 10 , p 28 - 28



 © 2004 Lippincott Williams & Wilkins, Inc. Volume 34(10)             October 2004             p 28 Vampire bat saliva puts a scare into blood clots [DRUG NEWS: STROKE]


A U.S. pharmaceutical company has acquired the rights to an experimental stroke treatment made from vampire bat saliva. The drug, desmoteplase, is designed to break up cerebral blood clots.

Desmoteplase is a genetically engineered version of a protein in a vampire bat's saliva that prevents clotting when the bat sucks blood from prey. The first in a new class of plasminogen activators, desmoteplase possesses a high fibrin selectivity that lets it dismantle a clot without affecting the coagulation system. This quality may decrease the risk of intracranial bleeding.

Desmoteplase seems to work within 9 hours of a stroke. Activase, the only clot-busting drug approved for acute ischemic stroke treatment, must be ...

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: